Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

WATERTOWN, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the ...

The werewolves turn to see him in the film's grim final shot. Howl is a simple B-movie, but that's all it needed to be. Its characters are generic but likable. Its creature effects are oddly charming.

Werewolf assumed Buy at Jefferies ahead of data for key cancer drug Jun. 06, 2023 12:13 PM ET Werewolf Therapeutics, Inc. (HOWL) Stock By: Dulan Lokuwithana, SA News Editor aluxum ...